Germline testing and genetic counseling in biliary tract cancer: an operative proposal to improve the state of art

References

• Rimini M, Puzzoni M, Pedica F, et al. Cholangiocarcinoma: new perspectives for new horizons. Expert Rev Gastroenterol Hepatol. 2021 Dec;15(12):1367–1383. Epub 2021 Nov 9. PMID: 34669536. doi: 10.1080/17474124.2021.1991313
   PubMed Web of Science ®Google Scholar
• Sia D, Villanueva A, Friedman SL, et al. Liver cancer cell of origin, molecular class, and effects on patient prognosis. Gastroenterology. 2017;152:745‐761. doi: 10.1053/j.gastro.2016.11.048
   PubMedGoogle Scholar
• Wu J, Yang S, Xu K, et al. Patterns and trends of liver cancer incidence rates in Eastern and Southeastern Asian Countries (1983–2007) and predictions to 2030. Gastroenterology. 2018 May;154(6):1719–1728.e5. Epub 2018 Mar 14. PMID: 29549041. doi: 10.1053/j.gastro.2018.01.033
   PubMed Web of Science ®Google Scholar
• Bertuccio P, Malvezzi M, Carioli G, et al. Global trends in mortality from intrahepatic and extrahepatic cholangiocarcinoma. J Hepatol. 2019 Jul;71(1):104–114. Epub 2019 Mar 23. PMID: 30910538. doi: 10.1016/j.jhep.2019.03.013
   PubMed Web of Science ®Google Scholar
• Valle J, Wasan H, Palmer DH, et al. Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer. N Engl J Med. 2010 Apr 8;362(14):1273–1281. PMID: 20375404. doi: 10.1056/NEJMoa0908721
   PubMed Web of Science ®Google Scholar
• Vogel A, Bridgewater J, Edeline J, et al. ESMO guidelines committee. electronic address: [email protected]. Biliary tract cancer: ESMO clinical practice guideline for diagnosis, treatment and follow-up. Ann Oncol. 2022 Nov 10;S0923-7534(22):04699–3. Epub ahead of print. PMID: 36372281. doi: 10.1016/j.annonc.2022.10.506
   Google Scholar
• Oh DY, He AR, Qin S, et al. A phase 3 randomized, double-blind, placebo-controlled study of durvalumab in combination with gemcitabine plus cisplatin (GemCis) in patients (pts) with advanced biliary tract cancer (BTC): TOPAZ-1. J Clin Oncol. 2022;40(4_suppl):378. doi: 10.1200/JCO.2022.40.4_suppl.378
   Web of Science ®Google Scholar
• Lowery MA, Ptashkin R, Jordan E, et al. Comprehensive molecular profiling of intra- hepatic and extrahepatic cholangiocarcinomas: potential targets for intervention. Clin Cancer Res. 2018;24:4154–4161. doi: 10.1158/1078-0432.CCR-18-0078
   PubMed Web of Science ®Google Scholar
• Nakamura H, Arai Y, Totoki Y, et al. Genomic spectra of biliary tract cancer. Nat Genet. 2015 Sep;47(9):1003–1010. Epub 2015 Aug 10. PMID: 26258846. doi: 10.1038/ng.3375
   PubMed Web of Science ®Google Scholar
• Simbolo M, Fassan M, Ruzzenente A, et al. Multigene mutational profiling of cholangiocarcinomas identifies actionable molecular subgroups. Oncotarget. 2014;5:2839–2852. doi: 10.18632/oncotarget.1943
   PubMed Web of Science ®Google Scholar
• Golan T, Hammel P, Reni M, et al. Maintenance olaparib for germline BRCA-mutated metastatic pancreatic cancer. N Engl J Med. 2019 Jul 25;381(4):317–327. Epub 2019 Jun 2. PMID: 31157963; PMCID: PMC6810605. doi: 10.1056/NEJMoa1903387
   PubMed Web of Science ®Google Scholar
• Robson M, Im SA, Senkus E, et al. Olaparib for metastatic breast cancer in patients with a germline BRCA mutation. N Engl J Med. 2017 Aug 10;377(6):523–533. doi:10.1056/NEJMoa1706450. Epub 2017 Jun 4. Erratum in: N Engl J Med. 2017 Oct 26;377(17):1700. PMID: 28578601.
   PubMed Web of Science ®Google Scholar
• Mecklin JP, Järvinen HJ, Virolainen M. The association between cholangiocarcinoma and hereditary nonpolyposis colorectal carcinoma. Cancer. 1992 Mar 1;69(5):1112–1114. doi: 10.1002/cncr.2820690508. PMID: 1310886.
   PubMed Web of Science ®Google Scholar
• Breast Cancer Linkage Consortium T. Cancer risks in BRCA2 mutation carriers. J Natl Cancer Inst. 1999 Aug 4;91(15):1310–1316. doi: 10.1093/jnci/91.15.1310. PMID: 10433620.
   PubMedGoogle Scholar
• Sharma MB, Carus A, Sunde L, et al. BRCA-associated pancreatico-biliary neoplasms: four cases illustrating the emerging clinical impact of genotyping. Acta Oncol. 2016;55(3):377–381. doi: 10.3109/0284186X.2015.1044023. Epub 2015 May 23. PMID: 26004055.
   PubMed Web of Science ®Google Scholar
• Momozawa Y, Sasai R, Usui Y, et al. Expansion of cancer risk profile for BRCA1 and BRCA2 pathogenic variants. JAMA Oncol. 2022 Jun 1;8(6):871–878. PMID: 35420638; PMCID: PMC9011177. doi: 10.1001/jamaoncol.2022.0476
   PubMed Web of Science ®Google Scholar
• Terashima T, Umemoto K, Takahashi H, et al. Germline mutations in cancer-predisposition genes in patients with biliary tract cancer. Oncotarget. 2019 Oct 15;10(57):5949–5957. doi: 10.18632/oncotarget.27224. PMID: 31666926; PMCID: PMC6800267.
   PubMedGoogle Scholar
• Wardell CP, Fujita M, Yamada T, et al. Genomic characterization of biliary tract cancers identifies driver genes and predisposing mutations. J Hepatol. 2018 May;68(5):959–969. Epub 2018 Jan 31. PMID: 29360550. doi: 10.1016/j.jhep.2018.01.009
   PubMed Web of Science ®Google Scholar
• Maynard H, Stadler ZK, Berger MF, et al. Germline alterations in patients with biliary tract cancers: a spectrum of significant and previously underappreciated findings. Cancer. 2020 Jan 1;126(9):1995–2002. Epub 2020 Feb 3. PMID: 32012241; PMCID: PMC7584349. doi: 10.1002/cncr.32740
   PubMed Web of Science ®Google Scholar
• Yu H, Xu Y, Gao W, et al. Comprehensive germline and somatic genomic profiles of Chinese patients with biliary tract cancer. Front Oncol 2022 Aug 22;12:930611. doi: 10.3389/fonc.2022.930611. PMID: 36072793; PMCID: PMC9441936.
   PubMed Web of Science ®Google Scholar
• Okawa Y, Iwasaki Y, Johnson TA, et al. Hereditary cancer variants and homologous recombination deficiency in biliary tract cancer. J Hepatol. 2023 Feb;78(2):333–342. Epub 2022 Oct 13. PMID: 36243179. doi: 10.1016/j.jhep.2022.09.025
   PubMed Web of Science ®Google Scholar
• Uson Junior PL, Kunze KL, Golafshar MA, et al. Germline cancer susceptibility gene testing in unselected patients with hepatobiliary cancers: a multi-center prospective study. Cancer Prev Res (Phila). 2022 Feb;15(2):121–128. doi: 10.1158/1940-6207.CAPR-21-0189. Epub 2021 Nov 15. PMID: 34782326; PMCID: PMC9662853.
   PubMed Web of Science ®Google Scholar
• Peltomäki P, Nyström M, Mecklin JP, et al. Lynch syndrome genetics and clinical implications. Gastroenterology. 2023 Jan 24;S0016-5085(23):00050–1. doi: 10.1053/j.gastro.2022.08.058. Epub ahead of print. PMID: 36706841.
   Google Scholar
• Perkhofer L, Golan T, Cuyle PJ, et al. Targeting DNA damage repair mechanisms in pancreas cancer. Cancers (Basel). 2021 Aug 24;13(17):4259. PMID: 34503069; PMCID: PMC8428219. doi: 10.3390/cancers13174259
   PubMed Web of Science ®Google Scholar
• Pal T, Cragun D, Lewis C, et al. A statewide survey of practitioners to assess knowledge and clinical practices regarding hereditary breast and ovarian cancer. Genet Test Mol Biomarkers. 2013 May;17(5):367–375. Epub 2013 Feb 28. PMID: 23448386; PMCID: PMC3634150. doi: 10.1089/gtmb.2012.0381
   PubMed Web of Science ®Google Scholar
• Kurian AW, Friese CR, Bondarenko I, et al. Second opinions from medical oncologists for early-stage breast cancer: prevalence, correlates, and consequences. JAMA Oncol. 2017 Mar 1;3(3):391–397. PMID: 28033448; PMCID: PMC5520652. doi: 10.1001/jamaoncol.2016.5652
   PubMed Web of Science ®Google Scholar
• Kurian AW, Li Y, Hamilton AS, et al. Gaps in incorporating germline genetic testing into treatment decision-making for early-stage breast cancer. J Clin Oncol. 2017 Jul 10;35(20): 2232–2239. doi: 10.1200/JCO.2016.71.6480. Epub 2017 Apr 12. PMID: 28402748; PMCID: PMC5501363.
   PubMed Web of Science ®Google Scholar
• Rimini M, Macarulla T, Burgio V, et al. Gene mutational profile of BRCAness and clinical implication in predicting response to platinum-based chemotherapy in patients with intrahepatic cholangiocarcinoma. Eur J Cancer. 2022 Aug;171:232–241. doi: 10.1016/j.ejca.2022.05.004. Epub 2022 Jun 21. PMID: 35749808.
   PubMed Web of Science ®Google Scholar